Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cannapharmarx Inc
(OP:
CPMD
)
0.0102
+0.0007 (+7.37%)
Streaming Delayed Price
Updated: 2:55 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cannapharmarx Inc
< Previous
1
2
Next >
CannaPharmaRx Receives Multiple Purchase Orders and Begins Delivery of Product
August 15, 2024
Via
ACCESSWIRE
Q1 2024 Financial Results
June 27, 2024
Via
ACCESSWIRE
CORRECTION FROM SOURCE: CannaPharmaRx to Host Investor Conference Call
May 20, 2024
Via
ACCESSWIRE
CannaPharmaRx to Host Investor Conference Call
May 20, 2024
Via
ACCESSWIRE
CannapharmaRx Pays Off Convertible Notes
April 02, 2024
Via
ACCESSWIRE
CannapharmaRx Receives First Purchase Order and Begins Shipment of Product
March 14, 2024
Via
ACCESSWIRE
CannaPharmaRx Completes First Harvests
March 12, 2024
Via
ACCESSWIRE
CannaPharmaRx CEO Provides Annual Update Message
February 15, 2024
Via
ACCESSWIRE
CannaPharmaRx to Hold Investor Conference Call
March 07, 2024
Via
ACCESSWIRE
CannaPharmaRx Executes Multi-Year Supply Agreement with ICAN to Create Distribution Network in the Latin Americas
March 05, 2024
Via
ACCESSWIRE
CannaPharmaRx Achieves IMC-GAP and GACP Certifications Completing a Significant Milestone Towards Revenue Acceleration
February 23, 2024
Via
ACCESSWIRE
CannaPharmaRx Finalizes Multi-Million Dollar Israeli Supply Agreement with Cantek
February 16, 2024
Via
ACCESSWIRE
CannaPharmaRx Expands Board of Directors
August 25, 2023
Via
ACCESSWIRE
CannaPharmaRx Appoints Dean Medwid as New CEO
June 23, 2023
Via
ACCESSWIRE
CannaPharmaRx Signs Agreement with Nasha Genetics
April 19, 2023
Via
ACCESSWIRE
CannaPharmaRx Signs Supply Agreement with Y.S.A Holdings for up to $15 Million Annually of Commercial Cannabis
March 30, 2023
Via
ACCESSWIRE
CannaPharmRx, Inc. Completes Purchase of LTB Management, an E- Commerce and Financial Platform Company, and Launches New Corporate Website
March 21, 2023
Via
ACCESSWIRE
CannaPharmRx, Inc. Adds to Revenue Streams by Purchasing E-Commerce and Financial Platform Company
February 21, 2023
Via
ACCESSWIRE
CannaPharmaRx Evaluates Investigation into Market Manipulation and Potentially Illegal Trading of Stock
February 01, 2023
Via
ACCESSWIRE
CannaPharmaRx Releases Year-in-Review Letter to Shareholders and Discusses Revenue Opportunities for 2023
January 30, 2023
Via
ACCESSWIRE
CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million Expected
January 11, 2023
Via
ACCESSWIRE
Canadian Cannabis; Down but Far from Out - Growth for 2023 and Beyond
December 22, 2022
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - December 22, 2022) - Investorideas.com, a leading investor news resource covering cannabis...
Via
Newsfile
Topics
Cannabis
Exposures
Cannabis
CannaPharmaRx Receives Cultivation License from Health Canada and Projects 2023 Revenue Over $30 Million
December 21, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Cannabis
Exposures
Cannabis
CannaPharmaRx Receives Cultivation License from Health Canada and Projects 2023 Annual Revenue over $30 Million
December 21, 2022
Via
ACCESSWIRE
Cannabis Cultivation Revenue Continues to Climb as Demand & Usage Grows Across North America
December 21, 2022
EQNX::TICKER_START (OTCPK:CPMD),(OTCQX:TCNNF),(OTCQX:CURLF),(NASDAQ:TLRY),(NASDAQ:ACB) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Cannabis
Derivatives
Exposures
COVID-19
Cannabis
Derivatives
CannaPharmaRx Receives Cultivation License from Health Canada and Projects 2023 Annual Revenue over $30 Million
December 21, 2022
Calgary, AB – December 21, 2022 – CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today it received its cultivation...
Via
FinancialNewsMedia
Topics
Cannabis
Exposures
Cannabis
CannaPharmaRx Secures New Strains for Declaration to be Incorporated Into Product Portfolio
December 19, 2022
Calgary, AB – December 19, 2022 – CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today it has secured new genetic strains...
Via
FinancialNewsMedia
Topics
Cannabis
Exposures
Cannabis
CannaPharmaRx Secures New Strains for Declaration to be Incorporated Into Product Portfolio
December 19, 2022
Via
ACCESSWIRE
CannaPharmaRx Files Response with Health Canada in Preparation for Cremona Facility Opening
September 07, 2022
Via
ACCESSWIRE
CannaPharmaRx Signs Collaboration and Offtake Agreement with Spring Medical Group for Up to $12 Million of Commercial Cannabis
August 24, 2022
Via
ACCESSWIRE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.